Don Dizon (he/him) is the Director of the Pelvic Malignancies Program at Lifespan Cancer Institute, Head of Community Outreach and Engagement at Legorreta Cancer Center, and Director of Medical Oncology at Rhode Island Hospital. Nationally he is the Vice Chair for Diversity, Equity, Inclusion, and Professional Integrity at SWOG Cancer Research Network. He also is a founding member of the Collaboration for Outcomes using Social Media in Oncology. His research foci include novel treatment of ovarian, uterine, and cervical cancers; communication; survivorship after cancer especially in sexuality; professional social media use; and advocacy on behalf of the sexual and gender minoritized (SGM) communities. He is a fellow of the American College of Physicians (FACP) and the American Society of Clinical Oncology (FASCO). \Dr. Dizon is on Instagram, Twitter, and TikTok as @drdonsdizon.
| Boardman CH, Brady WE, Dizon DS, Kunos CA, Moore KN, Zanotti KM, Matthews C, Cosin JA, Aghajanian C, Fracasso PM. "A Phase I Evaluation of Extended Field Radiation Therapy With Concomitant Cisplatin Chemotherapy Followed by Paclitaxel and Carboplatin Chemotherapy in Women With Cervical Carcinoma Metastatic to the Para-aortic Lymph Nodes: An NRG Oncology/Gynecologic Oncology Group Study." Gynecologic Oncology, vol. 151, no. 2, 2018, pp. 202-207. |
| Aghajanian C, Filiaci V, Dizon DS, Carlson JW, Powell MA, Secord AA, Tewari KS, Bender DP, O'Malley DM, Stuckey A, Gao J, Dao F, Soslow RA, Lankes HA, Moore K, Levine DA. "A phase II study of frontline paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus, or ixabepilone/carboplatin/bevacizumab in advanced/recurrent endometrial cancer." Gynecologic Oncology, vol. 150, no. 2, 2018, pp. 274-281. |
| MacLaughlan David S, Marjon N, English D, Purington N, Han SS, Dizon DS. "Palliative Total Pelvic Exenteration for Gynecologic Cancers: A Cross-sectional Study of Society of Gynecologic Oncology Members." International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, vol. 28, no. 9, 2018, pp. 1796-1804. |
| Lopresti, Mary, Rizack, Tina, Dizon, Don S. "Sexuality, fertility and pregnancy following breast cancer treatment." Gland Surgery, vol. 7, no. 4, 2018, pp. 404-410. |
| Jandial DA, Brady WE, Howell SB, Lankes HA, Schilder RJ, Beumer JH, Christner SM, Strychor S, Powell MA, Hagemann AR, Moore KN, Walker JL, DiSilvestro PA, Duska LR, Fracasso PM, Dizon DS. "A phase I pharmacokinetic study of intraperitoneal bortezomib and carboplatin in patients with persistent or recurrent ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study." Gynecologic Oncology, vol. 145, no. 2, 2017, pp. 236-242. |
| Jandial DA, Brady WE, Howell SB, Lankes HA, Schilder RJ, Beumer JH, Christner SM, Strychor S, Powell MA, Hagemann AR, Moore KN, Walker JL, DiSilvestro PA, Duska LR, Fracasso PM, Dizon DS. "A phase I pharmacokinetic study of intraperitoneal bortezomib and carboplatin in patients with persistent or recurrent ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study." Gynecologic Oncology, vol. 145, no. 2, 2017, pp. 236-242. |
| Thaker PH, Salani R, Brady WE, Lankes HA, Cohn DE, Mutch DG, Mannel RS, Bell-McGuinn KM, Di Silvestro PA, Jelovac D, Carter JS, Duan W, Resnick KE, Dizon DS, Aghajanian C, Fracasso PM. "A phase I trial of paclitaxel, cisplatin, and veliparib in the treatment of persistent or recurrent carcinoma of the cervix: an NRG Oncology Study (NCT#01281852)." Annals of Oncology, vol. 28, no. 3, 2017, pp. 505-511. |
| McCourt CK, Deng W, Dizon DS, Lankes HA, Birrer MJ, Lomme MM, Powell MA, Kendrick JE, Saltzman JN, Warshal D, Tenney ME, Kushner DM, Aghajanian C. "A phase II evaluation of ixabepilone in the treatment of recurrent/persistent carcinosarcoma of the uterus, an NRG Oncology/Gynecologic Oncology Group study." Gynecologic Oncology, vol. 144, no. 1, 2017, pp. 101-106. |
| Pesek SE, King HM, Koelliker S, Raker C, Edmonson D, Dizon DS, Gass J. "Axillary Ultrasound Fine Needle Aspiration Biopsy: Is There a Role in the Post Z-0011 Era?." American Journal of Clinical Oncology, 2017. |
| Gass JS, Onstad M, Pesek S, Rojas K, Fogarty S, Stuckey A, Raker C, Dizon DS. "Breast-Specific Sensuality and Sexual Function in Cancer Survivorship: Does Surgical Modality Matter?." Annals of Surgical Oncology, vol. 24, no. 11, 2017, pp. 3133-3140. |
| Burstein HJ, Krilov L, Aragon-Ching JB, Baxter NN, Chiorean EG, Chow WA, De Groot JF, Devine SM, DuBois SG, El-Deiry WS, Epstein AS, Heymach J, Jones JA, Mayer DK, Miksad RA, Pennell NA, Sabel MS, Schilsky RL, Schuchter LM, Tung N, Winkfield KM, Wirth LJ, Dizon DS. "Clinical Cancer Advances 2017: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology." Journal of Clinical Oncology, vol. 35, no. 12, 2017, pp. 1341-1367. |
| Lax T, Dizon DS, Birrer M, Long A, Del Carmen M, Goodman A, Krasner C, Penson RT, Growdon W, Camargo CA Jr, Banerji A. "Extended carboplatin infusion does not reduce frequency of hypersensitivity reaction at initiation of retreatment in patients with recurrent platinum-sensitive ovarian cancer." The Journal of Allergy and Clinical Immunology: In Practice, vol. 5, no. 1, 2017, pp. 177-178. |
| Preti EP, Landoni F, Colombo N, Dizon DS. "How to Address Sexual Problems in Female Cancer Patients." Oncology (Williston Park, N.Y.), vol. 31, no. 4, 2017, pp. 258-62, 264. |
| Dizon DS. "Neoadjuvant chemotherapy for newly diagnosed ovarian cancer: It's all about selection." Gynecologic Oncology, vol. 144, no. 2, 2017, pp. 241-242. |
| Dizon DS. "PARP inhibitors for targeted treatment in ovarian cancer." The Lancet, 2017. |
| Dittrich C, Stiefel F, Kiss A, Dizon DS. "Reply to the letter to the editor 'Integrating communication as a core skill in the global curriculum for medical oncology' by Horlait et al." Annals of Oncology, vol. 28, no. 4, 2017, pp. 905-906. |
| Sedrak MS, Dizon DS, Anderson PF, Fisch MJ, Graham DL, Katz MS, Kesselheim JC, Miller RS, Thompson MA, Utengen A, Attai DJ, Collaboration for Outcomes on Social Media in Oncology (COSMO). "The emerging role of professional social media use in oncology." Future oncology (London, England), vol. 13, no. 15, 2017, pp. 1281-1285. |
| Koh WJ, Greer BE, Abu-Rustum NR, Campos SM, Cho KR, Chon HS, Chu C, Cohn D, Crispens MA, Dizon DS, Dorigo O, Eifel PJ, Fisher CM, Frederick P, Gaffney DK, Han E, Higgins S, Huh WK, Lurain JR 3rd, Mariani A, Mutch D, Nagel C, Nekhlyudov L, Fader AN, Remmenga SW, Reynolds RK, Tillmanns T, Ueda S, Valea FA, Wyse E, Yashar CM, McMillian N, Scavone J. "Vulvar Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology." Journal of the National Comprehensive Cancer Network : JNCCN, vol. 15, no. 1, 2017, pp. 92-120. |
| Dizon DS. "What's the Harm?." The oncologist, 2017. |
| Penson RT, Sales E, Sullivan L, Borger DR, Krasner CN, Goodman AK, del Carmen MG, Growdon WB, Schorge JO, Boruta DM, Castro CM, Dizon DS, Birrer MJ. "A SNaPshot of potentially personalized care: Molecular diagnostics in gynecologic cancer." Gynecologic Oncology, vol. 141, no. 1, 2016, pp. 108-12. |
| Scalia-Wilbur J, Colins BL, Penson RT, Dizon DS. "Breast Cancer Risk Assessment: Moving Beyond BRCA 1 and 2." Seminars in radiation oncology, vol. 26, no. 1, 2016, pp. 3-8. |
| Bychkovsky BL, Ferreyra ME, Strasser-Weippl K, Herold CI, de Lima Lopes G Jr, Dizon DS, Schmeler KM, Del Carmen M, Randall TC, Nogueira-Rodrigues A, de Carvalho Calabrich AF, St Louis J, Vail CM, Goss PE. "Cervical cancer control in Latin America: A call to action." Cancer, vol. 122, no. 4, 2016, pp. 502-14. |
| Simone CG, Markham MJ, Dizon DS. "Chemotherapy in ovarian germ cell tumors: A systematic review." Gynecologic Oncology, vol. 141, no. 3, 2016, pp. 602-607. |
| Dizon DS, Krilov L, Cohen E, Gangadhar T, Ganz PA, Hensing TA, Hunger S, Krishnamurthi SS, Lassman AB, Markham MJ, Mayer E, Neuss M, Pal SK, Richardson LC, Schilsky R, Schwartz GK, Spriggs DR, Villalona-Calero MA, Villani G, Masters G. "Clinical Cancer Advances 2016: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology." Journal of Clinical Oncology, vol. 34, no. 9, 2016, pp. 987-1011. |
| Leung MW, Goldfarb S, Dizon DS. "Communication About Sexuality in Advanced Illness Aligns With a Palliative Care Approach to Patient-Centered Care." Current Oncology Reports, vol. 18, no. 2, 2016, pp. 11. |
| Katz MS, Utengen A, Anderson PF, Thompson MA, Attai DJ, Johnston C, Dizon DS. "Disease-Specific Hashtags for Online Communication About Cancer Care." JAMA Oncology, vol. 2, no. 3, 2016, pp. 392-4. |
| Krzystyniak J, Ceppi L, Dizon DS, Birrer MJ. "Epithelial ovarian cancer: the molecular genetics of epithelial ovarian cancer." Annals of Oncology, vol. 27 Suppl 1, 2016, pp. i4-i10. |
| Dittrich C, Kosty M, Jezdic S, Pyle D, Berardi R, Bergh J, El-Saghir N, Lotz JP, Österlund P, Pavlidis N, Purkalne G, Awada A, Banerjee S, Bhatia S, Bogaerts J, Buckner J, Cardoso F, Casali P, Chu E, Close JL, Coiffier B, Connolly R, Coupland S, De Petris L, De Santis M, de Vries EG, Dizon DS, Duff J, Duska LR, Eniu A, Ernstoff M, Felip E, Fey MF, Gilbert J, Girard N, Glaudemans AW, Gopalan PK, Grothey A, Hahn SM, Hanna D, Herold C, Herrstedt J, Homicsko K, Jones DV Jr, Jost L, Keilholz U, Khan S, Kiss A, Köhne CH, Kunstfeld R, Lenz HJ, Lichtman S, Licitra L, Lion T, Litière S, Liu L, Loehrer PJ, Markham MJ, Markman B, Mayerhoefer M, Meran JG, Michielin O, Moser EC, Mountzios G, Moynihan T, Nielsen T, Ohe Y, Öberg K, Palumbo A, Peccatori FA, Pfeilstöcker M, Raut C, Remick SC, Robson M, Rutkowski P, Salgado R, Schapira L, Schernhammer E, Schlumberger M, Schmoll HJ, Schnipper L, Sessa C, Shapiro CL, Steele J, Sternberg CN, Stiefel F, Strasser F, Stupp R, Sullivan R, Tabernero J, Travado L, Verheij M, Voest E, Vokes E, Von Roenn J, Weber JS, Wildiers H, Yarden Y. "ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016." ESMO open, vol. 1, no. 5, 2016, pp. e000097. |
| Dittrich C, Kosty M, Jezdic S, Pyle D, Berardi R, Bergh J, El Saghir N, Lotz JP, Österlund P, Pavlidis N, Purkalne G, ESMO/ASCO Global Curriculum Working Group. "ESMO/ASCO recommendations for a Global Curriculum (GC) in medical oncology-edition 2016." Annals of Oncology, vol. 27, no. 8, 2016, pp. 1378-81. |
| Birrer N, Chinchilla C, Del Carmen M, Dizon DS. "Is Hormone Replacement Therapy Safe in Women With a BRCA Mutation?: A Systematic Review of the Contemporary Literature." American Journal of Clinical Oncology, 2016. |
| Dizon DS, Birrer MJ. "Making a Difference: Distinguishing Two Primaries From Metastasis in Synchronous Tumors of the Ovary and Uterus." JNCI Journal of the National Cancer Institute, vol. 108, no. 6, 2016, pp. djv442. |
| Hall TR, Dizon DS. "Neoadjuvant chemotherapy for advanced epithelial ovarian cancer." Clinical advances in hematology & oncology : H&O, vol. 14, no. 4, 2016, pp. 262-8. |
| Wright AA, Bohlke K, Armstrong DK, Bookman MA, Cliby WA, Coleman RL, Dizon DS, Kash JJ, Meyer LA, Moore KN, Olawaiye AB, Oldham J, Salani R, Sparacio D, Tew WP, Vergote I, Edelson MI. "Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline." Journal of Clinical Oncology, vol. 34, no. 28, 2016, pp. 3460-73. |
| Wright AA, Bohlke K, Armstrong DK, Bookman MA, Cliby WA, Coleman RL, Dizon DS, Kash JJ, Meyer LA, Moore KN, Olawaiye AB, Oldham J, Salani R, Sparacio D, Tew WP, Vergote I, Edelson MI. "Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline." Gynecologic Oncology, vol. 143, no. 1, 2016, pp. 3-15. |
| Katz A, Dizon DS. "Sexuality After Cancer: A Model for Male Survivors." The journal of sexual medicine, vol. 13, no. 1, 2016, pp. 70-8. |
| Attai DJ, Sedrak MS, Katz MS, Thompson MA, Anderson PF, Kesselheim JC, Fisch MJ, Graham DL, Utengen A, Johnston C, Miller RS, Dizon DS, Collaboration for Outcomes on Social Media in Oncology (COSMO). "Social media in cancer care: highlights, challenges & opportunities." Future oncology (London, England), vol. 12, no. 13, 2016, pp. 1549-52. |
| Bychkovsky BL, Dizon DS, Sikov WM. "Systemic Therapies for Nonmetastatic Breast Cancer: The Role of Neoadjuvant and Adjuvant Chemotherapy and the Use of Endocrine Therapy." Clinical obstetrics and gynecology, vol. 59, no. 4, 2016, pp. 756-771. |
| Clark MA, Ott M, Rogers ML, Politi MC, Miller SC, Moynihan L, Robison K, Stuckey A, Dizon D. "Advance care planning as a shared endeavor: completion of ACP documents in a multidisciplinary cancer program." Psycho-Oncology, vol. 26, no. 1, 2015, pp. 67-73. |
| Bradford LS, Rauh-Hain JA, Schorge J, Birrer MJ, Dizon DS. "Advances in the management of recurrent endometrial cancer." American Journal of Clinical Oncology, vol. 38, no. 2, 2015, pp. 206-12. |
| Boswell EN, Dizon DS. "Breast cancer and sexual function." Translational andrology and urology, vol. 4, no. 2, 2015, pp. 160-8. |
| Masters GA, Krilov L, Bailey HH, Brose MS, Burstein H, Diller LR, Dizon DS, Fine HA, Kalemkerian GP, Moasser M, Neuss MN, O'Day SJ, Odenike O, Ryan CJ, Schilsky RL, Schwartz GK, Venook AP, Wong SL, Patel JD. "Clinical cancer advances 2015: Annual report on progress against cancer from the American Society of Clinical Oncology." Journal of Clinical Oncology, vol. 33, no. 7, 2015, pp. 786-809. |
| Joseph N, Clark RM, Dizon DS, Lee MS, Goodman A, Boruta D Jr, Schorge JO, Del Carmen MG, Growdon WB. "Delay in chemotherapy administration impacts survival in elderly patients with epithelial ovarian cancer." Gynecologic Oncology, vol. 137, no. 3, 2015, pp. 401-5. |
| Foley O, Dizon D, Schmeler K, Del Carmen M. "Development of a Breast Cancer Advocacy and Access Health Program in Nicaragua." The Breast Journal, vol. 21, no. 5, 2015, pp. 570-1. |
| Dizon DS. "Don Dizon, MD, on Sexual Health After a Cancer Diagnosis, and the Disappointments of Precision Medicine." Oncology (Williston Park, N.Y.), vol. 29, no. 11, 2015, pp. 865-6. |
| McMeekin S, Dizon D, Barter J, Scambia G, Manzyuk L, Lisyanskaya A, Oaknin A, Ringuette S, Mukhopadhyay P, Rosenberg J, Vergote I. "Phase III randomized trial of second-line ixabepilone versus paclitaxel or doxorubicin in women with advanced endometrial cancer." Gynecologic Oncology, vol. 138, no. 1, 2015, pp. 18-23. |
| Strasser-Weippl K, Chavarri-Guerra Y, Villarreal-Garza C, Bychkovsky BL, Debiasi M, Liedke PE, Soto-Perez-de-Celis E, Dizon D, Cazap E, de Lima Lopes G Jr, Touya D, Nunes JS, St Louis J, Vail C, Bukowski A, Ramos-Elias P, Unger-Saldaña K, Brandao DF, Ferreyra ME, Luciani S, Nogueira-Rodrigues A, de Carvalho Calabrich AF, Del Carmen MG, Rauh-Hain JA, Schmeler K, Sala R, Goss PE. "Progress and remaining challenges for cancer control in Latin America and the Caribbean." The Lancet Oncology, vol. 16, no. 14, 2015, pp. 1405-38. |
| Lum LG, Thakur A, Al-Kadhimi Z, Colvin GA, Cummings FJ, Legare RD, Dizon DS, Kouttab N, Maizel A, Colaiace W, Liu Q, Rathore R. "Targeted T-cell Therapy in Stage IV Breast Cancer: A Phase I Clinical Trial." Clin Cancer Res , vol. 21, no. 10, 2015, pp. 2305-14. |
| Dizon DS. "Toward eubiosia: bridging oncology and palliative care." The oncologist, vol. 20, no. 1, 2015, pp. 5-6. |
| Koh WJ, Greer BE, Abu-Rustum NR, Apte SM, Campos SM, Cho KR, Chu C, Cohn D, Crispens MA, Dizon DS, Dorigo O, Eifel PJ, Fisher CM, Frederick P, Gaffney DK, George S, Han E, Higgins S, Huh WK, Lurain JR 3rd, Mariani A, Mutch D, Fader AN, Remmenga SW, Reynolds RK, Tillmanns T, Valea FA, Yashar CM, McMillian NR, Scavone JL, National Comprehensive Cancer Network. "Uterine Sarcoma, Version 1.2016: Featured Updates to the NCCN Guidelines." Journal of the National Comprehensive Cancer Network : JNCCN, vol. 13, no. 11, 2015, pp. 1321-31. |
| Duska LR, Blessing JA, Rotmensch J, Mannel RS, Hanjani P, Rose PG, Dizon DS. "A Phase II evaluation of ixabepilone (IND #59699, NSC #710428) in the treatment of recurrent or persistent leiomyosarcoma of the uterus: an NRG Oncology/Gynecologic Oncology Group Study." Gynecologic Oncology, vol. 135, no. 1, 2014, pp. 44-8. |
| Dizon DS, Sill MW, Schilder JM, McGonigle KF, Rahman Z, Miller DS, Mutch DG, Leslie KK. "A phase II evaluation of nintedanib (BIBF-1120) in the treatment of recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study." Gynecologic Oncology, vol. 135, no. 3, 2014, pp. 441-5. |
| Dizon DS, Birrer MJ. "Advances in the diagnosis and treatment of uterine sarcomas." Discovery medicine, vol. 17, no. 96, 2014, pp. 339-45. |
| Robison K, Clark L, Eng W, Wu L, Raker C, Clark M, Tejada-Berges T, Dizon DS. "Cervical cancer prevention: Asian-American women's knowledge and participation in screening practices." Women's Health Issues, vol. 24, no. 2, 2014, pp. e231-6. |
| Dizon DS. "Guilt and the burden on oncology providers." The oncologist, vol. 19, no. 5, 2014, pp. 441-2. |
| Duska LR, Dizon DS. "Improving quality of life in female cancer survivors: current status and future questions." Future oncology (London, England), vol. 10, no. 6, 2014, pp. 1015-26. |
| Rauh-Hain JA, Clemmer J, Clark RM, Bradford LS, Growdon WB, Goodman A, Boruta DM 2nd, Dizon DS, Schorge JO, del Carmen MG. "Management and outcomes for elderly women with vulvar cancer over time." BJOG: An International Journal of Obstetrics & Gynaecology, vol. 121, no. 6, 2014, pp. 719-27; discussion 727. |
| Dizon DS. "My Father's Final Lesson." The oncologist, vol. 19, no. 10, 2014, pp. 1110-1. |
| Dizon DS. "Narratives in oncology." The oncologist, vol. 19, no. 8, 2014, pp. 789. |
| Reynolds K, Sarangi S, Bardia A, Dizon DS. "Precision medicine and personalized breast cancer: combination pertuzumab therapy." Pharmacogenomics and personalized medicine, vol. 7, 2014, pp. 95-105. |
| DeSimone M, Spriggs E, Gass JS, Carson SA, Krychman ML, Dizon DS. "Sexual dysfunction in female cancer survivors." American Journal of Clinical Oncology, vol. 37, no. 1, 2014, pp. 101-6. |
| Dizon DS, Suzin D, McIlvenna S. "Sexual health as a survivorship issue for female cancer survivors." The oncologist, vol. 19, no. 2, 2014, pp. 202-10. |
| Dizon DS, Mackay HJ, Thomas GM, Werner TL, Kohn EC, Hess D, Rose PG, Covens AL. "State of the science in cervical cancer: where we are today and where we need to go." Cancer, vol. 120, no. 15, 2014, pp. 2282-8. |
| Duska LR, Fader AN, Dizon DS. "Survivorship in gynecologic cancer: enduring the treatment toward a new normal." American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Meeting, 2014, pp. e288-94. |
| Denlinger CS, Ligibel JA, Are M, Baker KS, Demark-Wahnefried W, Dizon D, Friedman DL, Goldman M, Jones L, King A, Ku GH, Kvale E, Langbaum TS, Leonardi-Warren K, McCabe MS, Melisko M, Montoya JG, Mooney K, Morgan MA, Moslehi JJ, O'Connor T, Overholser L, Paskett ED, Peppercorn J, Raza M, Rodriguez MA, Syrjala KL, Urba SG, Wakabayashi MT, Zee P, McMillian NR, Freedman-Cass DA, National comprehensive cancer network. "Survivorship: healthy lifestyles, version 2.2014." Journal of the National Comprehensive Cancer Network : JNCCN, vol. 12, no. 9, 2014, pp. 1222-37. |
| Denlinger CS, Ligibel JA, Are M, Baker KS, Demark-Wahnefried W, Dizon D, Friedman DL, Goldman M, Jones L, King A, Ku GH, Kvale E, Langbaum TS, Leonardi-Warren K, McCabe MS, Melisko M, Montoya JG, Mooney K, Morgan MA, Moslehi JJ, O'Connor T, Overholser L, Paskett ED, Peppercorn J, Raza M, Rodriguez MA, Syrjala KL, Urba SG, Wakabayashi MT, Zee P, McMillian NR, Freedman-Cass DA. "Survivorship: immunizations and prevention of infections, version 2.2014." Journal of the National Comprehensive Cancer Network : JNCCN, vol. 12, no. 8, 2014, pp. 1098-111. |
| Denlinger CS, Ligibel JA, Are M, Baker KS, Demark-Wahnefried W, Dizon D, Friedman DL, Goldman M, Jones L, King A, Ku GH, Kvale E, Langbaum TS, Leonardi-Warren K, McCabe MS, Melisko M, Montoya JG, Mooney K, Morgan MA, Moslehi JJ, O'Connor T, Overholser L, Paskett ED, Peppercorn J, Raza M, Rodriguez MA, Syrjala KL, Urba SG, Wakabayashi MT, Zee P, McMillian NR, Freedman-Cass DA, National Comprehensive Cancer Network. "Survivorship: nutrition and weight management, Version 2.2014. Clinical practice guidelines in oncology." Journal of the National Comprehensive Cancer Network : JNCCN, vol. 12, no. 10, 2014, pp. 1396-406. |
| Denlinger CS, Ligibel JA, Are M, Baker KS, Demark-Wahnefried W, Dizon D, Friedman DL, Goldman M, Jones L, King A, Ku GH, Kvale E, Langbaum TS, Leonardi-Warren K, McCabe MS, Melisko M, Montoya JG, Mooney K, Morgan MA, Moslehi JJ, O'Connor T, Overholser L, Paskett ED, Peppercorn J, Raza M, Rodriguez MA, Syrjala KL, Urba SG, Wakabayashi MT, Zee P, McMillian NR, Freedman-Cass DA. "Survivorship: screening for cancer and treatment effects, version 2.2014." Journal of the National Comprehensive Cancer Network : JNCCN, vol. 12, no. 11, 2014, pp. 1526-31. |
| Bregar A, Robison K, Dizon DS. "Update on the chemotherapeutic management of endometrial cancer." Clinical advances in hematology & oncology : H&O, vol. 12, no. 10, 2014, pp. 659-65. |
| Penson RT, Dizon DS, Birrer MJ. "Clear cell cancer of the ovary." Current opinion in oncology, vol. 25, no. 5, 2013, pp. 553-7. |
| Politi MC, Dizon DS, Frosch DL, Kuzemchak MD, Stiggelbout AM. "Importance of clarifying patients' desired role in shared decision making to match their level of engagement with their preferences." BMJ, vol. 347, 2013, pp. f7066. |
| Rizack T, Gass JS, Legare RD, Sakr BJ, Dizon DS. "Is tumor board relevant?." The Breast Journal, vol. 19, no. 3, 2013, pp. 351-3. |
| Stuckey A, Schutzer M, Rizack T, Dizon D. "Locally advanced vulvar cancer in elderly women: is chemoradiation beneficial?." American Journal of Clinical Oncology, vol. 36, no. 3, 2013, pp. 279-82. |
| Wei W, Dizon D, Vathipadiekal V, Birrer MJ. "Ovarian cancer: genomic analysis." Annals of Oncology, vol. 24 Suppl 10, 2013, pp. x7-15. |
| Rauh-Hain JA, Guseh SH, Esselen KM, Growdon WB, Schorge JO, Horowitz NS, Krasner CN, del Carmen MG, Birrer MJ, Dizon DS. "Patterns of recurrence in patients treated with bevacizumab in the primary treatment of advanced epithelial ovarian cancer." International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, vol. 23, no. 7, 2013, pp. 1219-25. |
| Gao J, Dizon DS. "Preparing for survivorship: quality of life in breast cancer survivors." The journal of sexual medicine, vol. 10 Suppl 1, 2013, pp. 16-20. |
| Dizon DS, Ambrosio AJ, Feltmate C, Wright AA, Campos SM, Viswanathan A, Cervical Cancer Special Interest Group of Dana Farber/Harvard Comprehensive Cancer Center Gynecologic Cancer Management Team. "Pushing the bar in treatment of cervical cancer: what can comprehensive cancer centers do on their own?." Gynecologic Oncology, vol. 131, no. 2, 2013, pp. 464-6. |
| Maclaughlan David S, Salzillo S, Bowe P, Scuncio S, Malit B, Raker C, Gass JS, Granai CO, Dizon DS. "Randomised controlled trial comparing hypnotherapy versus gabapentin for the treatment of hot flashes in breast cancer survivors: a pilot study." BMJ Open, vol. 3, no. 9, 2013, pp. e003138. |
| Falk SJ, Dizon DS. "Sexual dysfunction in women with cancer." Fertility and Sterility, vol. 100, no. 4, 2013, pp. 916-21. |
| Meng X, Dizon DS, Yang S, Wang X, Zhu D, Thiel KW, Leslie KK. "Strategies for Molecularly Enhanced Chemotherapy to Achieve Synthetic Lethality in Endometrial Tumors with Mutant p53." Obstetrics and gynecology international, vol. 2013, 2013, pp. 828165. |
| Roque DR, Cronin B, Robison K, Lopes V, Rizack T, Dizon DS. "The effects of age on treatment and outcomes in women with stages IB1-IIB cervical cancer." Journal of geriatric oncology, vol. 4, no. 4, 2013, pp. 374-81. |
| Dizon DS, Politi MC, Back AL. "The power of words: discussing decision making and prognosis." American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Meeting, 2013, pp. 442-6. |
| Dizon DS. "Where do antiangiogenic agents belong in the treatment algorithm for ovarian cancer?." American Journal of Clinical Oncology, vol. 36, no. 5, 2013, pp. 519-25. |
| Sabatini ME, Dizon DS. "Why DOMA is unconstitutional, beyond the traditional views of same sex relationships." Journal of assisted reproduction and genetics, vol. 30, no. 6, 2013, pp. 861. |
| Dizon DS, Blessing JA, Penson RT, Drake RD, Walker JL, Johnston CM, Disilvestro PA, Fader AN. "A phase II evaluation of belinostat and carboplatin in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal carcinoma: a Gynecologic Oncology Group study." Gynecologic Oncology, vol. 125, no. 2, 2012, pp. 367-71. |
| Campos SM, Dizon DS. "Antimitotic inhibitors." Hematology/oncology clinics of North America, vol. 26, no. 3, 2012, pp. 607-28, viii-ix. |
| Hill EK, Dizon DS. "Medical therapy of endometrial cancer: current status and promising novel treatments." Drugs, vol. 72, no. 5, 2012, pp. 705-13. |
| Stuckey A, Dizon DS. "Novel antiangiogenic therapies in ovarian cancer." Women's health (London, England), vol. 8, no. 4, 2012, pp. 447-53. |
| Dizon DS, Damstrup L, Finkler NJ, Lassen U, Celano P, Glasspool R, Crowley E, Lichenstein HS, Knoblach P, Penson RT. "Phase II activity of belinostat (PXD-101), carboplatin, and paclitaxel in women with previously treated ovarian cancer." International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, vol. 22, no. 6, 2012, pp. 979-86. |
| Horowitz NS, Olawaiye AB, Borger DR, Growdon WB, Krasner CN, Matulonis UA, Liu JF, Lee J, Brard L, Dizon DS. "Phase II trial of erlotinib in women with squamous cell carcinoma of the vulva." Gynecologic Oncology, vol. 127, no. 1, 2012, pp. 141-6. |
| Sakr BJ, Dizon DS. "Breast cancer: adjuvant modalities." Clinical obstetrics and gynecology, vol. 54, no. 1, 2011, pp. 150-6. |
| Politi MC, Clark MA, Ombao H, Dizon D, Elwyn G. "Communicating uncertainty can lead to less decision satisfaction: a necessary cost of involving patients in shared decision making?." Health Expectations, vol. 14, no. 1, 2011, pp. 84-91. |
| Tsiapali E, Schmidt MM, Dizon D, Steinhoff M, Gass J. "Patterns of cellular distribution with the sentinel node positive for breast cancer." International journal of breast cancer, vol. 2011, 2011, pp. 873987. |
| Dizon DS, Sill MW, Gould N, Rubin SC, Yamada SD, Debernardo RL, Mannel RS, Eisenhauer EL, Duska LR, Fracasso PM. "Phase I feasibility study of intraperitoneal cisplatin and intravenous paclitaxel followed by intraperitoneal paclitaxel in untreated ovarian, fallopian tube, and primary peritoneal carcinoma: a gynecologic oncology group study." Gynecologic Oncology, vol. 123, no. 2, 2011, pp. 182-6. |
| Starikov R, Goldman R, Dizon DS, Kostadinov S, Carr S. "Placental mesenchymal dysplasia presenting as a twin gestation with complete molar pregnancy." Obstetrics and gynecology, vol. 118, no. 2 Pt 2, 2011, pp. 445-9. |
| Kuroki L, Stuckey A, Hirway P, Raker CA, Bandera CA, DiSilvestro PA, Granai CO, Legare RD, Sakr BJ, Dizon DS. "Addressing clinical trials: can the multidisciplinary Tumor Board improve participation? A study from an academic women's cancer program." Gynecologic Oncology, vol. 116, no. 3, 2010, pp. 295-300. |
| Makhija S, Amler LC, Glenn D, Ueland FR, Gold MA, Dizon DS, Paton V, Lin CY, Januario T, Ng K, Strauss A, Kelsey S, Sliwkowski MX, Matulonis U. "Clinical activity of gemcitabine plus pertuzumab in platinum-resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer." Journal of Clinical Oncology, vol. 28, no. 7, 2010, pp. 1215-23. |
| Stuckey A, Dizon D, Scalia Wilbur J, Kent J, Tejada-Berges T, Gass J, Legare R. "Clinical characteristics and choices regarding risk-reducing surgery in BRCA mutation carriers." Gynecologic and obstetric investigation, vol. 69, no. 4, 2010, pp. 270-3. |
| Kristjansdottir K, Dizon D. "HER-dimerization inhibitors: evaluating pertuzumab in women's cancers." Expert opinion on biological therapy, vol. 10, no. 2, 2010, pp. 243-50. |
| Penson RT, Dizon DS, Cannistra SA, Roche MR, Krasner CN, Berlin ST, Horowitz NS, Disilvestro PA, Matulonis UA, Lee H, King MA, Campos SM. "Phase II study of carboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab as first-line chemotherapy for advanced mullerian tumors." Journal of Clinical Oncology, vol. 28, no. 1, 2010, pp. 154-9. |
| Dizon DS. "Treatment options for advanced endometrial carcinoma." Gynecologic Oncology, vol. 117, no. 2, 2010, pp. 373-81. |
| Dizon DS, Schutzer ME, Politi MC, Linkletter CD, Miller SC, Clark MA. "Advance Care Planning Decisions of Women with Cancer: Provider Recognition and Stability of Choices." Journal of Psychosocial Oncology, vol. 27, no. 4, 2009, pp. 383-95. |
| Schwartz J, Toste B, Dizon DS. "Chemotherapy toxicity in gynecologic cancer patients with a body surface area (BSA)>2 m2." Gynecologic Oncology, vol. 114, no. 1, 2009, pp. 53-6. |
| Sikov WM, Dizon DS, Strenger R, Legare RD, Theall KP, Graves TA, Gass JS, Kennedy TA, Fenton MA. "Frequent pathologic complete responses in aggressive stages II to III breast cancers with every-4-week carboplatin and weekly paclitaxel with or without trastuzumab: a Brown University Oncology Group Study." Journal of Clinical Oncology, vol. 27, no. 28, 2009, pp. 4693-700. |
| McCourt C, Dessie S, Bradley AM, Schwartz J, Brard L, Dizon DS. "Is there a taxane-free interval that predicts response to taxanes as a later-line treatment of recurrent ovarian or primary peritoneal cancer?." International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, vol. 19, no. 3, 2009, pp. 343-7. |
| Shah N, Dizon DS. "New-generation platinum agents for solid tumors." Future oncology (London, England), vol. 5, no. 1, 2009, pp. 33-42. |
| Dizon DS, Blessing JA, McMeekin DS, Sharma SK, Disilvestro P, Alvarez RD. "Phase II trial of ixabepilone as second-line treatment in advanced endometrial cancer: gynecologic oncology group trial 129-P." Journal of Clinical Oncology, vol. 27, no. 19, 2009, pp. 3104-8. |
| Dizon DS. "Quality of life after breast cancer: survivorship and sexuality." The Breast Journal, vol. 15, no. 5, 2009, pp. 500-4. |
| Perez K, Gadgil M, Dizon DS. "Sexual ramifications of medical illness." Clinical obstetrics and gynecology, vol. 52, no. 4, 2009, pp. 691-701. |
| Dizon DS, Perez K, DiSilvestro P, Taneja C, Ilson D. "Stage IV small bowel carcinoma mimicking advanced ovarian cancer." The American Surgeon, vol. 75, no. 9, 2009, pp. 864-5. |
| Dizon DS, Restivo A, Lomme M, Charbonneau N, Brard L, Hughes T, Weitzen S, Legare R, Granai CO, Disilvestro P. "For women receiving chemotherapy for clinically apparent early ovarian cancer, is there a benefit to surgical staging?." American Journal of Clinical Oncology, vol. 31, no. 1, 2008, pp. 39-42. |
| Dizon DS, Makhija S. "HER dimerization inhibitors: developing pertuzumab as an anticancer agent in women's oncology." Expert opinion on drug discovery, vol. 3, no. 11, 2008, pp. 1363-9. |
| Dizon DS, Schwartz J, Kemeny N. "Regional chemotherapy: a focus on hepatic artery infusion for colorectal cancer liver metastases." Surgical oncology clinics of North America, vol. 17, no. 4, 2008, pp. 759-71, viii. |
| SGO Breast Cancer Task Force., Orr J Jr, Kelley J 3rd, Dizon D, Escobar P, Fleming E, Gemignani M, Hetzel D, Hoskins W, Kieback D, Kilgore L, LaPolla J, Lewin S, Lucci J, Markman M, Pothuri B, Powell CB, Tejada-Berges T. "Society of gynecologic oncologists position paper: breast cancer care." Gynecologic Oncology, vol. 110, no. 1, 2008, pp. 7-12. |
| Dizon DS, Beheshti J, McDonough K, Gass J. "The differential diagnosis of dyspnea in a woman with metastatic breast cancer--consideration beyond pulmonary embolism." The Breast Journal, vol. 14, no. 1, 2008, pp. 90-1. |
| Hensley ML, Dizon D, Derosa F, Venkatraman E, Sabbatini P, Chi DS, Dupont J, Colevas AD, Spriggs D, Aghajanian C. "A phase I trial of BMS-247550 (NSC# 710428) and gemcitabine in patients with advanced solid tumors." Investigational new drugs, vol. 25, no. 4, 2007, pp. 335-41. |
| Bhandari T, Dizon DS, Taneja C, Gass J, Masko GD, Strenger R. "Clinical characteristics of women presenting with skin-only recurrence of breast cancer." The American Journal of Surgery, vol. 194, no. 4, 2007, pp. 494-6. |
| Gass JS, Weitzen S, Clark M, Dizon DS. "Defining social support systems for women with breast cancer." The American Journal of Surgery, vol. 194, no. 4, 2007, pp. 501-3. |
| Dizon, D. S., Gass, J. S., Bandera, C., Weitzen, S., Clark, M. "Does one person provide it all? Primary support and advanced care planning for women with cancer." Journal of Clinical Oncology, vol. 25, no. 11, 2007, pp. 1412-1416. |
| Schwartz JR, Bandera C, Bradley A, Brard L, Legare R, Granai CO, Dizon DS. "Does the platinum-free interval predict the incidence or severity of hypersensitivity reactions to carboplatin? The experience from Women and Infants' Hospital." Gynecologic Oncology, vol. 105, no. 1, 2007, pp. 81-3. |
| Gordinier ME, Dizon DS, Weitzen S, Disilvestro PA, Moore RG, Granai CO. "Oral thalidomide as palliative chemotherapy in women with advanced ovarian cancer." Journal of Palliative Medicine, vol. 10, no. 1, 2007, pp. 61-6. |
| Wiggins DL, Wood R, Granai CO, Dizon DS. "Sex, intimacy, and the gynecologic oncologists: survey results of the New England Association of Gynecologic Oncologists (NEAGO)." Journal of Psychosocial Oncology, vol. 25, no. 4, 2007, pp. 61-70. |
| Kalkunte S, Swamy N, Dizon DS, Brard L. "Benzyl isothiocyanate (BITC) induces apoptosis in ovarian cancer cells in vitro." Journal of experimental therapeutics & oncology, vol. 5, no. 4, 2006, pp. 287-300. |
| Dizon DS, Schwartz J, Rojan A, Miller J, Pires L, Disilvestro P, Gordinier ME, Moore R, Granai CO, Legare RD. "Cross-sensitivity between paclitaxel and docetaxel in a women's cancers program." Gynecologic Oncology, vol. 100, no. 1, 2006, pp. 149-51. |
| Gordinier ME, Dizon DS, Fleming EL, Weitzen S, Schwartz J, Parker LP, Granai CO. "Elevated body mass index does not increase the risk of palmar-plantar erythrodysesthesia in patients receiving pegylated liposomal doxorubicin." Gynecologic Oncology, vol. 103, no. 1, 2006, pp. 72-4. |
| Dizon DS, Tejada-Berges T, Koelliker S, Steinhoff M, Granai CO. "Ovarian cancer associated with testosterone supplementation in a female-to-male transsexual patient." Gynecologic and obstetric investigation, vol. 62, no. 4, 2006, pp. 226-8. |
| Satyan KS, Swamy N, Dizon DS, Singh R, Granai CO, Brard L. "Phenethyl isothiocyanate (PEITC) inhibits growth of ovarian cancer cells by inducing apoptosis: role of caspase and MAPK activation." Gynecologic Oncology, vol. 103, no. 1, 2006, pp. 261-70. |
| Somasundar P, Gass J, Steinhoff M, Koeliker S, Dizon D, Cady B, Taneja C. "Role of ultrasound-guided axillary fine-needle aspiration in the management of invasive breast cancer." The American Journal of Surgery, vol. 192, no. 4, 2006, pp. 458-61. |
| Dizon DS, Weitzen S, Rojan A, Schwartz J, Miller J, Disilvestro P, Gordinier ME, Moore R, Tejada-Berges T, Pires L, Legare R, Granai CO. "Two for good measure: six versus eight cycles of carboplatin and paclitaxel as adjuvant treatment for epithelial ovarian cancer." Gynecologic Oncology, vol. 100, no. 2, 2006, pp. 417-21. |
| Gordinier ME, Dizon DS. "Dyspnea during thalidomide treatment for advanced ovarian cancer." Annals of Pharmacotherapy, vol. 39, no. 5, 2005, pp. 962-5. |
| Aghajanian C, Dizon DS, Sabbatini P, Raizer JJ, Dupont J, Spriggs DR. "Phase I trial of bortezomib and carboplatin in recurrent ovarian or primary peritoneal cancer." Journal of Clinical Oncology, vol. 23, no. 25, 2005, pp. 5943-9. |
| Krychman ML, Carter J, Aghajanian CA, Dizon DS, Castiel M. "Chemotherapy-induced dyspareunia: a case study of vaginal mucositis and pegylated liposomal doxorubicin injection in advanced stage ovarian carcinoma." Gynecologic Oncology, vol. 93, no. 2, 2004, pp. 561-3. |
| Leitao MM Jr, Boyd J, Hummer A, Olvera N, Arroyo CD, Venkatraman E, Baergen RN, Dizon DS, Barakat RR, Soslow RA. "Clinicopathologic analysis of early-stage sporadic ovarian carcinoma." The American Journal of Surgical Pathology, vol. 28, no. 2, 2004, pp. 147-59. |
| Dizon DS. "Incorporating targeted treatments into standard regimens: whither the role of established doses?." Cancer investigation, vol. 22, no. 6, 2004, pp. 954. |
| Sabbatini P, Aghajanian C, Leitao M, Venkatraman E, Anderson S, Dupont J, Dizon D, O'Flaherty C, Bloss J, Chi D, Spriggs D. "Intraperitoneal cisplatin with intraperitoneal gemcitabine in patients with epithelial ovarian cancer: results of a phase I/II Trial." Clin Cancer Res , vol. 10, no. 9, 2004, pp. 2962-7. |
| Sabbatini P, Aghajanian C, Dizon D, Anderson S, Dupont J, Brown JV, Peters WA, Jacobs A, Mehdi A, Rivkin S, Eisenfeld AJ, Spriggs D. "Phase II study of CT-2103 in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma." Journal of Clinical Oncology, vol. 22, no. 22, 2004, pp. 4523-31. |
| Leitao MM Jr, Hummer A, Dizon DS, Aghajanian C, Hensley M, Sabbatini P, Venkatraman E, Spriggs DR. "Platinum retreatment of platinum-resistant ovarian cancer after nonplatinum therapy." Gynecologic Oncology, vol. 91, no. 1, 2003, pp. 123-9. |
| Abu-Rustum NR, Sonoda Y, Chi DS, Teoman H, Dizon DS, Venkatraman E, Barakat RR. "The effects of CO2 pneumoperitoneum on the survival of women with persistent metastatic ovarian cancer." Gynecologic Oncology, vol. 90, no. 2, 2003, pp. 431-4. |
| Dizon DS, Dupont J, Anderson S, Sabbatini P, Hummer A, Aghajanian C, Spriggs D. "Treatment of recurrent ovarian cancer: a retrospective analysis of women treated with single-agent carboplatin originally treated with carboplatin and paclitaxel. The Memorial Sloan-Kettering Cancer Center experience." Gynecologic Oncology, vol. 91, no. 3, 2003, pp. 584-90. |
| Aghajanian C, Soignet S, Dizon DS, Pien CS, Adams J, Elliott PJ, Sabbatini P, Miller V, Hensley ML, Pezzulli S, Canales C, Daud A, Spriggs DR. "A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies." Clin Cancer Res , vol. 8, no. 8, 2002, pp. 2505-11. |
| Dizon DS, Sabbatini PJ, Aghajanian C, Hensley ML, Spriggs DR. "Analysis of patients with epithelial ovarian cancer or fallopian tube carcinoma retreated with cisplatin after the development of a carboplatin allergy." Gynecologic Oncology, vol. 84, no. 3, 2002, pp. 378-82. |
| Dizon DS, Kemeny NE. "Intrahepatic arterial infusion of chemotherapy: clinical results." Seminars in oncology, vol. 29, no. 2, 2002, pp. 126-35. |
| Dizon DS, Hensley ML, Poynor EA, Sabbatini P, Aghajanian C, Hummer A, Venkatraman E, Spriggs DR. "Retrospective analysis of carboplatin and paclitaxel as initial second-line therapy for recurrent epithelial ovarian carcinoma: application toward a dynamic disease state model of ovarian cancer." Journal of Clinical Oncology, vol. 20, no. 5, 2002, pp. 1238-47. |
| Shrimdkandada S, Fu SQ, Yin LH, Guo XY, Nanakorn T, Peng XY, Dizon D, Lin D, Cooperberg M, Won JH, Deisseroth A. "Methods for Chemoprotection and Chemosensitization : MDR-1 For Chemoprotection Using Retroviruses to Modify Hematopoietic Cells and Cytosine Deaminase for Chemosensitization Using Adenoviral Vectors to Modify Epithelian Neoplastic Cells." Methods in molecular medicine, vol. 35, 2000, pp. 609-16. |
U10 CA180838: SWOG Network Group Operations Center of the NCTN
PI: Charles Blanke, MD (Oregon Health Sciences University)
Role: Chairman, Digital Engagement Committee
HU0001-16-2-0006: Henry M Jackson Foundation for the Advancement of Military Medicine
Role: Social media manager, Gynecologic Cancer Center of Excellence’s Ovarian Cancer Registry
American Cancer Society: Randomized trial of a multimodal sexual dysfunction intervention for hematopoietic stem cell transplants survivors
PI, Areej El-Jawarhi (MGH Cancer Center)
Role: Co-Investigator
Kazia Pharmaceuticals: Phase I Study of Cantrixil in Patients With Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer (NCT02903771)
Role: US Lead PI
UM1CA233080: SIMPRO Research Center: Integration of PROs for Symptom Management in Oncology Practice.
Overall PI: Deb Schrag (Dana Farber Cancer Institute)
Role: Site Principal Investigator
Bristol Myers Squibb: A Phase II Randomized Trial of Nivolumab +/- Ipilimumab for Ovarian and Extrarenal Clear Cell Carcinomas. (BrUOG 354)
Role: Principal Investigator
Bristol Myers Squibb: A Pilot Feasibility study incorporating Nivolumab to tailored radiation therapy with concomitant cisplatin in the treatment of patients with cervical cancer. (BrUOG 355)
Role: Principal Investigator
| Year | Degree | Institution |
|---|---|---|
| 1995 | MD | University of Rochester |
| 1991 | BA | University of Rochester |
Lifespan Cancer Institute
Legorreta Cancer Center at Brown University
Rhode Island Hospital
The Center for Digital Health
| Professor of Surgery. Brown University , 2021- |
| Professor of Medicine, Research Scholar Track. 2019- |
| Associate Director, Community Outreach and Engagement. Legorreta Cancer Center at Brown University, 2019- |
| Director, Medical Oncology. Rhode Island Hospital, 2017- |
